•   Led by Future Ventures, includes top healthcare and technology funds Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures

•   Proceeds will support creating new technology for artificial intelligence-accelerated therapeutic development and advancing Wilson disease program into the clinic 

TORONTO – January 7, 2020. Deep Genomics, the ...

Toronto, Ontario ​– September 25, 2019. Deep Genomics, the leading AI therapeutics company, announced today that its proprietary artificial intelligence-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare, serious, and potentially life-threatening genetic disorder.

“This is ...

Toronto, Ontario – June 26, 2019 at 9:00 AM EDT. Deep Genomics, the leading AI therapeutics company, announced today that Peter Barton Hutt, Senior Counsel at Covington & Burling and former Chief Counsel of the U.S. Food and Drug Administration, has joined the company ...

Toronto, Ontario – June 24, 2019 at 9:00 AM EDT. Deep Genomics, the leading AI therapeutics company, announced today that James Dowling, M.D., Ph.D., is joining the team as Chief Medical Officer, effective today.

“Deep Genomics has identified therapeutic opportunities addressing hundreds of ...

TORONTO, Ontario, Canada – June 18, 2019. Deep Genomics, the leading AI therapeutics company, announced today that the output of its discovery pipeline has quadrupled in the past year and that it has appointed Johan Fransson, Ph.D. as Head of Preclinical Research, effective immediately.

“We ...

CAMBRIDGE, Mass. U.S.A. and TORONTO, Ontario, Canada, April 10, 2018 - Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics Inc., the leading AI therapeutics company that is building a ...

For the first time, machine learning will be used at every step of drug discovery to identify candidates for treating genetically defined metabolic and neurodegenerative disorders.

TORONTO, Ontario, Canada, March 26, 2018 - Deep Genomics, the leading AI therapeutics company that has built a platform using ...

AI platform to unlock new classes of anti-sense oligonucleotide therapies.

TORONTO, Ontario, Canada, September 25, 2017 - Deep Genomics, the leading AI therapeutics company, received a USD $13 million equity investment led by Khosla Ventures, one of the top venture capital firms. They are accompanied by ...